TABLE 3.
Distribution of histological characteristics in the liver transplant recipients at 1-y follow-up with and without recurrent NAFLD based on NASH CRN staging criteria
| Parameters | One-year protocol liver biopsy | |||
|---|---|---|---|---|
| All patients | NAFLD-No | NAFLD-Yes | P | |
| N = 21 | N = 6 | N = 15 | ||
| Steatosis (% of cohort) | N(%) | N(%) | N(%) | |
| None [<5%] | 6 (28.6) | 6 (100) | 0 | .0001 |
| Mild [5%–33%] | 7 (33.3) | 0 | 7 (46.7) | |
| Moderate [33%–66%] | 4 (19.0) | 0 | 4 (26.7) | |
| Severe [>66%] | 4 (19.0) | 0 | 4 (26.7) | |
| Lobular inflammation | ||||
| Absent | 7 (33.3) | 3 (50.0) | 4 (26.7) | .46 |
| <2 foci/field | 12 (57.1) | 3 (50.0) | 9 (60.0) | |
| 2–4 foci/field | 2 (9.5) | 0 | 2 (13.3) | |
| >4 foci/field | 0 | 0 | 0 | |
| Cytological ballooning | ||||
| None | 13 (61.9) | 6 (100) | 7 (46.7) | .08 |
| Few | 7 (33.3) | 0 | 7 (46.7) | |
| More than few | 1 (4.8) | 0 | 1 (6.7) | |
| Portal inflammation | ||||
| None | 13 (61.9) | 3 (50.0) | 10 (66.7) | .29 |
| Mild | 5 (23.8) | 1 (16.7) | 4 (26.7) | |
| More than mild | 3 (14.3) | 2 (33.3) | 1 (6.7) | |
| Mallory bodies | ||||
| None | 19 (9.0) | 6 (100) | 13 (86.7) | 1.0 |
| Present | 2 (9.5) | 0 | 2 (13.3) | |
| NAFLD activity score | ||||
| None [NAS 0]a | 4 (19.0) | 4 (66.7) | 0 | 0.003 |
| Mild [NAS 1–2] | 7 (33.3) | 2 (33.3) | 5 (33.3) | |
| Moderate [NAS 3–4] | 6 (28.6) | 0 | 6 (40.0) | |
| Severe [NAS 5–8] | 4 (19.0) | 0 | 4 (26.7) | |
| NASH diagnosis category | ||||
| Definite NASH | 4 (19.0) | 0 | 4 (26.7) | 0.28 |
| Fibrosis and NASH CRN | ||||
| Stage 0 [absent] | 12 (57.1) | 4 (66.7) | 8 (53.3) | 0.50 |
| Stage 1 | 3 (14.3) | 0 | 3 (20.0) | |
| Stage 2 [zone 3 perisinusoidal fibrosis with portal/periportal fibrosis] | 6 (28.6) | 2 (33.3) | 4 (26.7) | |
| Stage 3 [bridging fibrosis] | 0 | 0 | 0 | |
| Stage 4 [cirrhosis] | 0 | 0 | 0 | |
CRN, clinical research network; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD activity score; NASH, nonalcoholic steatohepatitis.